Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

• Published in: Journal of hematology and oncology Vol. 15; no. 1; pp. 24 - 58
• Main Authors: Wu, Mengling, Huang, Qianrui, Xie, Yao, Wu, Xuyi, Ma, Hongbo, Zhang, Yiwen, Xia, Yong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.03.2022; BioMed Central; BMC
• Subjects: Animals; B cells; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; Cancer; Chemotherapy; Combination therapy; Drug resistance; Drug therapy; Health aspects; Humans; Immune Checkpoint Inhibitors - pharmacology; Immunotherapy; Immunotherapy - methods; Neoplasms - drug therapy; Neoplasms - immunology; PD-1/PD-L1; PD-L1 regulation; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Review; T cells; Tumor Microenvironment; PD-L1 regulation; Combination therapy; Immunotherapy; PD-1/PD-L1

Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certai...